Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
Demo Company

Study Reveals Basis for Development of a Universal Flu Vaccine

By BiotechDaily International staff writers
Posted on 26 Mar 2013
Researchers attempting to develop a "universal" flu vaccine have suggested that a multifocal approach based on primed immune cells and virus specific non-neutralizing antibodies may result in long-term protection from multiple strains of the influenza virus.

Investigators at the University of Pennsylvania (Philadelphia, USA) based their work on studies that showed that T lymphocytes were capable of mediating protection against multiple viral strains through recognition of internal, more conserved, influenza virus proteins.

They reported in the March 14, 2013, online edition of the journal PLOS Pathogens that influenza virus-specific CD8+ T-cells or virus-specific non-neutralizing antibodies were each relatively ineffective at conferring protective immunity alone. However, when administered together virus-specific CD8 T-cells and non-neutralizing antibodies cooperatively elicited robust protective immunity. This synergistic improvement in protective immunity was dependent, at least in part, on alveolar macrophages and/or other lung phagocytes.

“The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model,” said senior author Dr. E. John Wherry, associate professor of microbiology at the University of Pennsylvania,. “Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine. Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T-cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential "universal" vaccine.”

Related Links:
University of Pennsylvania



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The ChilliBlock modular system for precise, controlled cooling and heatingof biological samples (Photo courtesy of Asynt).

Modular Cooling/Heating System Safeguards Temperature-Sensitive Biological Samples

A new modular system designed for precise, controlled cooling and heating of biological samples in microplates, vials and Eppendorf tubes is now available for biotech, clinical, and life science laboratories.... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.